Table 3.

HPV (non-) vaccine-type positivity among women with incident hrHPV infections

Age grouphrHPV positiveBivalent vaccine typesaNonbivalent vaccine typesbPolyvalent vaccine typescNonpolyvalent vaccine typesd
Nn% (95% CI)n% (95% CI)n% (95% CI)n% (95% CI)
POBASCAM
29–331084440.7 (31.4–50.6)7771.3 (61.8–79.6)8881.5 (72.9–88.3)3431.4 (22.9–41.1)
34–381254838.4 (29.8–47.5)8971.2 (62.4–78.9)9475.2 (66.7–82.5)4536.0 (27.6–45.1)
39–43682536.8 (25.4–49.3)4769.1 (56.7–79.8)4769.1 (56.7–79.8)2435.3 (24.1–47.8)
44–48561323.2 (13.0–36.4)4580.4 (67.6–89.8)3460.7 (46.8–73.5)2442.3 (29.7–56.8)
49–53451635.6 (21.9–51.2)3066.7 (51.0–80.0)3168.9 (53.4–81.8)1533.3 (20.0–49.0)
54–5621838.1 (18.1–61.6)1361.9 (38.4–81.9)1676.2 (52.8–91.8)523.8 (8.2–47.2)
Total42315436.4 (31.8–41.2)30171.1 (66.6–78.4)31073.3 (68.8–77.4)14734.8 (30.2–39.3)
Linear effect: regression coefficient (SE)e−0.011 (0.014)0.004 (0.015)−0.025 (0.147)0.014 (0.014)
Nonlinear effect: regression coefficient (SE)f0.002 (0.002)−0.002 (0.002)0.004 (0.002)g−0.003 (0.002)
NTCC
24–28652640.0 (28.0–52.9)4772.3 (59.8–82.7)4670.8 (58.2–81.4)2843.1 (30.8–56.0)
29–33532852.8 (38.6–66.7)3260.4 (46.0–73.5)4483.0 (70.2–91.9)1528.3 (16.8–42.3)
34–38401025.0 (12.7–41.2)2380.0 (64.4–90.9)2767.5 (50.9–81.4)1845.0 (29.3–61.5)
39–43291034.5 (17.9–54.3)2379.3 (60.3–92.0)1551.7 (32.5–70.6)1551.7 (32.5–70.6)
44–4824833.3 (15.6–55.3)1875.0 (53.3–90.2)1250 (29.1–70.9)1250.0 (29.1–70.9)
49–5312433.3 (9.9–65.1)1083.3 (51.6–97.9)866.7 (34.9–90.1)433.3 (9.9–65.1)
54–568450.0 (15.7–84.3)675.0 (34.9–96.8)787.5 (47.3–99.7)337.5 (8.5–75.5)
57–602002100.0 (0.16–100.0)150.0 (1.26–98.7)150.0 (1.3–98.7)
Total2339038.6 (32.3–45.2)17073.0 (66.8–78.6)16068.7 (62.3–74.6)9641.2 (34.8–47.8)
Linear effect: regression coefficient (SE)e,g−0.022 (0.229)0.043 (0.025)−0.046 (0.024)0.030 (0.021)
Nonlinear effect: regression coefficient (SE)f,g0.006 (0.030)h−0.004 (0.003)0.010 (0.004)h−0.005 (0.003)
  • aBivalent vaccine types includes HPV types 16 and 18.

  • bNonbivalent vaccine types includes HPV types 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68.

  • cPolyvalent vaccine types includes HPV types 16, 18, 31, 33, 45, 52, and 58.

  • dNonpolyvalent vaccine types includes HPV types 35, 39, 51, 56, 59, and 68.

  • eRegression coefficient and standard error of the linear term in logistic regression models, including age as continuous variable and adjusted for the number of infections.

  • fRegression coefficient and standard error of the nonlinear (quadratic) term in logistic regression models, including age and age squared as continuous variable and adjusted for the number of infections.

  • gRestricted to the same age range as POBASCAM (29–56 years). The classification in HPV types is not mutually exclusive and totals of bivalent + nonbivalent and polyvalent + nonpolyvalent types exceed the 100% as a result of multiple type infections.

  • hP < 0.05.